Table 2.

Treatment exposure and outcomes

IDLine of anti–PD-1/PD-L1 therapyPrior therapyAnti–PD-1/PD-L1 therapyTime on therapy (Mos)Best responseTTP from the date of treatment cessation (Mos)Subsequent therapy (best response)
11N/APD-L1+2.7PR1.4Cabozantanib (PR)
23Gemcitabine + sutent (VEGF TKI), sutentPD-13.8PR3Cabozantanib (PR)
33Sutent + angiopoetin inhibitor, temsirolimus (mTOR inhibitor) +avastin (VEGF mAb)PD-13.7PR3.4Axitinib (SD, 17% growth), sorafenib (NE), pazopanib (NE)
41N/APD-L1+0.7SD, 9% shrinkage4.5aBSC, pazopanib (TBD)
52SutentPD-14.1PR4.7Cabozantanib (SD, 15% shrinkage)
61N/APD-L1+2.7PR5.6Cabozantanib (SD, 9% shrinkage), axitinib (TBD)
81N/APD-1+10.2SD, 15% shrinkage7.8bN/A
92SutentPD-16SD, 4% shrinkage8.2N/A
106Sutent, axitinib (VEGF TKI), everolimus (mTOR inhibitor), pazopanib, sutentPD-16.1SDc9.5N/A
122AxitinibPD-15.5SD, 1% shrinkage10.6N/A
142Sunitinib + angiopoetin inhibitorPD-L17SD, 10% shrinkage18.4Pazopanib (SD, 11% growth)
  • Abbreviations: N/A, not applicable as patient remains progression-free; PD-1+, anti–PD-1 combination therapy, PD-1, anti–PD-1 monotherapy; PD-L1, anti–PD-L1 monotherapy; PD-L1+, anti–PD-L1 combination therapy; Mos, months; SD, stable disease with tumor shrinkage; CR, complete response; PR, partial response; TBD, to be determined; BSC, best supportive care; OS, overall survival.

  • aTTP from the date of treatment cessation stopped at time of transition to best supportive care.

  • bTTP from the date of treatment cessation for this patient stopped at the time of progressing metastatic lesion. These patients developed tumor growth in isolated areas treated with surgical intervention only. NE, not evaluable; VEGF, vascular endothelial growth factor; TKI, tyrosine kinase inhibitor; mTOR, mechanistic target of rapamycin; mAb, monoclonal antibody.

  • c% change not available.